High mortality rates in conservatively managed patients with acute coronary syndrome

References

• The joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined – A consensus document of the joint European Society of Cardiology/American College of Cardiology Committee for redefinition of myocardial infarction. Eur Heart J. 2000; 21: 1502–13
   PubMed Web of Science ®Google Scholar
• Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CV, McFadden E, et al. Management of acute coronary syndromes in patients presenting without ST-segment elevation. Eur Heart J. 2002; 23: 1809–40
   PubMed Web of Science ®Google Scholar
• Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2003; 24: 28–66
   PubMed Web of Science ®Google Scholar
• Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of 23 randomised trials. Lancet 2003; 361: 13–20
   PubMed Web of Science ®Google Scholar
• Fox KA, Goodman SG, Klein W, Brieger D, Steg PG, Dabbous O, et al. Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2002; 23: 1177–89
   PubMed Web of Science ®Google Scholar
• The clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New Engl J Med. 2001; 345: 494–502
   PubMed Web of Science ®Google Scholar
• Otterstad JE, Platou ES, Mangschau A, Endresen K. Hjerteinfarkt. Diagnostikk og behandling. Hjerteforum 2002; 15 Suppl 3
   Google Scholar
• Fibrinolytic Therapy Trialists’ (FTT) Collaboration Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and morbidity results from all randomised trials of more than 1000 patients. Lancet. 1994; 343: 311–22
   PubMed Web of Science ®Google Scholar
• Sinnaeve P, Alexander J, Belmans A, Bogaerts K, Langer A, Diaz R, et al. One year follow-up of the ASSENT-2 trial: A double-blinded, randomised comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction. Am Heart J. 2003; 146: 27–32
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Califf RM, Van de Werf F, Willerson JT, White HD, Armstrong PW, et al. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomised trial. JAMA. 2002; 288: 2130–5
   PubMed Web of Science ®Google Scholar
• Hasdai D, Behar S, Wallentin L, Danchin N, Gitt AK, Boersma E, et al. A prospective survey of the characteristics, treatment and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin. The Euro Heart Study of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J. 2002; 23: 1190–1201
   PubMed Web of Science ®Google Scholar
• Carruthers KF, Dabbous OH, Flather MD, Starkey I, Jacob A, Macleod D, et al. Contemporary management of acute coronary syndromes: Does the practice match the evidence? The global registry of acute coronary events (GRACE). Heart. 2005; 91: 290–8
   PubMed Web of Science ®Google Scholar
• Terkelsen CJ, Lassen JF, Nørgaard BL, Gerds JC, Jensen T, Gøtzsche LB, et al. Mortality rates in patients with ST-elevation vs. non-ST-elevation acute myocardial infarction: Observations from an unselected cohort. Eur Heart J. 2005; 26: 18–26
   PubMed Web of Science ®Google Scholar
• Bjorklund E, Lindahl B, Stenestrand U, Swahn E, Dellborg M, Pehrsson K, et al. Outcome of ST-elevation myocardial infarction treated with thrombolysis in the unselected population is vastly different from samples of eligible patients in a large-scale clinical trial. Am Heart J. 2004; 148: 566–73
   PubMed Web of Science ®Google Scholar
• Hjortshøj S, Otterstad JE, Lindahl B, Danielsen R, Pulkki K, Ravkilde J. Biochemical diagnosis of myocardial infarction evolves toward ESC/ACC consensus: Experiences from the Nordic countries. Scand Cardiovasc J. 2005; 39: 159–66
   PubMed Web of Science ®Google Scholar
• Poole-Wilson PA, Lubsen J, Kirwan BA, van Dalen FJ, Wagener G, Danchin N, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): Randomised controlled trial. Lancet. 2004; 364: 849–57
   PubMed Web of Science ®Google Scholar
• Otterstad JE, St John Sutton MG, Froeland GS, Holme I, Skjaerpe T, Hall C. Prognostic value of two-dimensional echocardiography and N-terminal proatrial natriuretic peptide following an acute myocardial infarction. Assessment of baseline values (2-7 days) and changes at 3 months in patients with a preserved systolic function. Eur Heart J. 2002; 23: 1011–20
   PubMed Web of Science ®Google Scholar
• Eagle KA, Goodman SG, Avezum A, Budaj A, Sullivan CM, Lopez-Sendon J, et al. Practice variations and missed opportunities for reperfusion in ST-segment-elevation myocardial infraction: Findings from the Global Registry of Acute Coronary Events (GRACE). Lancet. 2002; 359: 373–7
   PubMed Web of Science ®Google Scholar
• De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2003; 24: 1601–10
   PubMed Web of Science ®Google Scholar
• Fox KA, Poole-Wilson PA, Clayton TC, Henderson RA, Shaw TR, Wheatley DJ, et al. 5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: The British Heart Foundation RITA 3 randomised trial. Lancet. 2005; 366: 914–20
   PubMed Web of Science ®Google Scholar
• Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, et al. A validated prediction model for all forms of acute coronary syndrome: Estimating the risk of 6-month postdischarge death in an international registry. JAMA. 2004; 291: 2727–33
   PubMed Web of Science ®Google Scholar